Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Critical Care Physicians (US)(?)

Council Members in this Study Group: 344

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Sabry Ayad, MD
Chairman of Anesthesiology and Critical Care
Westgate Medical Anesthesia Group

Sabry Ayad, MD, is a member of Westgate Medical Anesthesia Group, a private practice that provides a full range of anesthesia services for local healthcare facilities in Ohio. Through his employment at Westgate Medical Anesthesia Group, he is the Chairman of Anesthesiology and Critical Care at Fairview...

Robert Aris, MD, Associate Professor of Medicine, University of North Carolina Chapel Hill - CCRobert Aris, MD
Associate Professor of Medicine
University of North Carolina Chapel Hill - CC

Robert Aris, MD, is an Associate Professor of Medicine at the University of North Carolina Chapel Hill. He is the Director of the Pulmonary Hypertension Program, the Lung Transplant Research Program and Inpatient Pulmonary Services. Dr. Aris has expertise in advanced lung diseases including cystic...

Michael Wechsler, MD
Associate Physician in Pulmonary and Critical Care
BRIGHAM AND WOMEN'S HOSPITAL

Michael Wechsler, MD, is an Associate Physician in the Pulmonary and Critical Care Division of Brigham and Women's Hospital in Boston and is on the faculty at Harvard Medical School. He is a member of the Steering Committee of the NIH's Asthma Clinical Research Network and is active in both basic and...

Glenn Rosen, MD
Associate Professor of Medicine
Stanford University Medical Center Auxiliary

Glenn Rosen, MD, is Associate Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at Stanford University with a joint appointment in Cancer Biology. Dr. Rosen has expertise in a wide variety of pulmonary diseases including lung cancer and pulmonary fibrosis. His basic research...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Cure is a strong word | 08-04-2008
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor

It is important to remember that there are many more "treatable" cancers diagnosed than curable cancers. The initiation of chemotherapy after surgical removal of a neoplasm is a signal that there may be undetectable metastatic disease.  You are therefore hoping for a cure but accepting the reality....

Mild PAH improved by early treatment with bosentan | 07-18-2008
Author: Robert Aris, MD, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC

While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit exclusively) FC II PAH patients.  This is important because the definition of functional class II is that a patient has a sight...

Peer reviewed literature on Ambrisentan, a selective ETRA for PAH | 06-10-2008
Author: Robert Aris, MD, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC

This Circulation paper is the first peer reviewed data on the 2 pivotal Phase III trials on ambrisentan that lead the FDA to approving it for the treatment of PAH in July 2007. This paper is critically important since all new research needs to withstand the rigor of peer-review for...

Singulair suicide story won't kill Merck | 04-02-2008
Author: Michael Wechsler, MD, Associate Physician in Pulmonary and Critical Care, BRIGHAM AND WOMEN'S HOSPITAL

Singulair helps millions of people suffering from asthma. While there are a few sporadic cases of suicide and depression among the millions of patients taking singulair, no causal link has been established and there is no clear mechanism of how singulair might even cause such effects.  In fact,...

Use of injectable zileuton may not be a panacea for asthma | 10-08-2007
Author: GLG Expert Contributor

Several questions arise about injectable Zileuton.  Inhaled steroids still remain the mainstay of theray for asthma.  Will patients accept the use of an injectable drug for asthma - if it results in infrequent dosing, it may be an acceptable option for patients.  Liver function tests...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Physician - Division Head
  • Owner
  • President
  • Medical Director

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-08-30T09:45:15.793